Content area

Abstract

As angiogenesis was recognized as a core hallmark of cancer growth and survival, several strategies have been implemented to target the tumour vasculature. Yet to date, attempts have rarely been so diverse, ranging from vessel growth inhibition and destruction to vessel normalization, reprogramming and vessel growth promotion. Some of these strategies, combined with standard of care, have translated into improved cancer therapies, but their successes are constrained to certain cancer types. This Review provides an overview of these vascular targeting approaches and puts them into context based on our subsequent improved understanding of the tumour vasculature as an integral part of the tumour microenvironment with which it is functionally interlinked. This new knowledge has already led to dual targeting of the vascular and immune cell compartments and sets the scene for future investigations of possible alternative approaches that consider the vascular link with other tumour microenvironment components for improved cancer therapy.

Various strategies have been proposed and implemented to target the tumour vasculature, which supports tumour growth and progression. However, to date they have had variable success. Guelfi et al. describe some of these approaches and discuss how our increased understanding of the interactions between tumour vessels and the immune compartment could help generate combination therapies that provide durable responses in patients with cancer.

Details

Title
Targeting the tumour vasculature: from vessel destruction to promotion
Author
Guelfi, Sophie 1   VIAFID ORCID Logo  ; Hodivala-Dilke, Kairbaan 2 ; Bergers, Gabriele 1   VIAFID ORCID Logo 

 VIB-KU Leuven Center for Cancer Biology and KU Leuven, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133) 
Pages
655-675
Publication year
2024
Publication date
Oct 2024
Publisher
Nature Publishing Group
ISSN
1474175X
e-ISSN
14741768
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3109554164
Copyright
© Springer Nature Limited 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.